No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CSTL Castle Biosciences
- 20.060
- +0.450+2.29%
Close Apr 23 16:00 ET
- 20.060
- 0.0000.00%
Post 16:01 ET
553.40MMarket Cap-9373P/E (TTM)
20.670High19.610Low198.46KVolume19.610Open19.610Pre Close4.00MTurnover0.74%Turnover RatioLossP/E (Static)27.59MShares26.70052wk High1.41P/B537.09MFloat Cap9.26052wk Low--Dividend TTM26.77MShs Float107.690Historical High--Div YieldTTM5.41%Amplitude9.260Historical Low20.130Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn
Castle Biosciences(CSTL.US) Officer Sells US$106.02K in Common Stock
$Castle Biosciences(CSTL.US)$ Officer MAETZOLD DEREK J sold 5,210 shares of common stock on Apr 12, 2024 at an average price of $20.35 for a total value of $106.02K.Source: Announcement What is statem
Form 144 | Castle Biosciences(CSTL.US) Officer Proposes to Sell 381.3K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 12, $Castle Biosciences(CSTL.US)$ Officer Derek Maetzold intends to sell 19,008 shares of its common stock on Apr 12, with a total market value of approximately $381.3K.
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2024,
Castle Biosciences(CSTL.US) Director Sells US$49,087.2 in Common Stock
$Castle Biosciences(CSTL.US)$ Director BRADBURY DANIEL sold 2,400 shares of common stock on Apr 8, 2024 at an average price of $20.453 for a total value of $49,087.2.Source: Announcement What is state
Castle Biosciences Celebrates Esophageal Cancer Awareness Month Through Advocacy and Educational Collaborations
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.
Comments
Despite impressive revenue growth, the high P/S ratio and average growth expectations make the share price seem overvalued. Predicted future revenues may not support this positive sentiment, risking shareholders' investments and potential investors paying a premium.
More Unpleasant Surprises Could Be In Store For Castle Biosciences, Inc.'s (NASDAQ:CSTL) Shares After Tumbling 25% 1
Castle Biosciences' progress over the last year is impressive, and it is well-positioned to raise more cash for growth with minimal dilution or borrowing. Its cash burn situation is not risky due to revenue growth and cash burn reduction.
Investors are confident in Castle Biosciences' future growth despite its high P/S ratio. The strong future revenue growth justifies the high P/S ratio, making a significant share price drop unlikely.
Derek Maetzold, president and CEO of Castle Biosciences, sees the robust revenue and test volume growth as a testament to their successful execution of growth initiatives. He is optimistic about the sustainability of this growth and momentum into 2024.
On watch
$Castle Biosciences(CSTL.US$ Keeping a close eye to see what comes out of this? (. New Data Highlights Clinical Utility and Performance of Castle Biosciences' Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference
Businesswire· 4 mins ago
Businesswire· 4 mins ago
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg